Vertex Pharmaceuticals (VRTX) Revenue — Quarter Ended Jun 30, 2024
Revenue decreased compared to the prior quarter but increased compared to the same quarter last year. The sequential decline ended a period of successive gains.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue decreased compared to the prior quarter but increased compared to the same quarter last year. The sequential decline ended a period of successive gains.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$2.6B
Revenue reported for this quarter.
Quarter-over-quarter
-1.7%
Change from the immediately preceding quarter.
Year-over-year
+6.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$10.3B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2023 | $2.5B | +6.4% |
| Dec 31, 2023 | $2.5B | +9.3% |
| Mar 31, 2024 | $2.7B | +13.3% |
| Jun 30, 2024 | $2.6B | +6.1% |
Revenue performance
Net product revenues were lower than the previous quarter, while remaining above the level of a year ago.
Quarterly comparison
Revenue declined from the preceding quarter, yet rose on a year-over-year basis.
What to watch
The sequential revenue decline is a notable change after several quarters of increases.